{"url_path":"/sec/coch/8-k/2026-06-25/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 ** **Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1840877/0001213900-26-072033-index.html","accession_number":"0001213900-26-072033","cik":"0001840877","ticker":"COCH","issuer_name":"Envoy Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840877/0001213900-26-072033-index.html","primary_entity_key":"0001840877","primary_entity_name":"Envoy Medical, Inc."},"word_count":238,"has_tables":true,"body_markdown":"**Item 5.02** **Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**\n\n \n\nOn\nJune 19, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Envoy Medical, Inc.\n(the “Company”), approved certain changes to the compensation of the Company’s Chief Executive Officer, Brent\nLucas. Mr. Lucas will receive an updated base salary of $420,000 per year and will be eligible for a cash bonus targeted at $105,000,\nwhich will be determined based on the achievement of certain strategic performance goals intended to be achieved during calendar years\n2026 and 2027.\n\n \n\nThe\nCommittee also approved the issuance to Mr. Lucas of 1,000,000 stock options and 1,000,000 restricted stock units (“RSUs”).\nThe stock options are exercisable at $0.634 per share (the most recent closing price of the Company’s Class A Common Stock\nprior to the grant date), will vest over a period of four years, and will have the Company’s other standard terms. The RSUs were\nissued on the form of Restricted Stock Unit Award Grant Notice and Award Agreement, which is filed herewith as Exhibit 10.1 and\nincorporated herein by reference, and will vest as of the date of the official notification by the U.S. Food and Drug Administration\n(FDA) that it has granted approval (including approval with conditions) for the Company’s Acclaim cochlear implant, provided that\nsuch announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030."}